Skip to main content

Advertisement

SpringerLink
Log in

Intensified, intermittent, low-dose intravenous cyclophosphamide together with oral alternate-day steroid therapy in lupus nephritis (long-term outcome)

  • Review
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

The objective of this study is to evaluate the efficacy, toxicity, and long-term outcome of low-dose IV cyclophosphamid therapy with repeated frequent intervals in combination with oral and IV methylprednisolone in patients with SLE nephritis. In this study, 113 patients diagnosed as having SLE and glomerulonephritis were assessed in between 1993 and 2002, with a median follow-up of 44.1±41.2 months. The patients were treated with 500 mg IV cyclophosphamide and 1 g IV methylprednisolone together with 60 mg/alternate-day oral methylprednisolone in a given schedule. The clinical and laboratory data were evaluated. There were significant improvements in the clinical and the laboratory parameters. Six patients died shortly after being hospitalized due to the disease activity itself. Eight patients were excluded from the study because of low compliance. The renal functions of the patients remained stable throughout the therapy; only 16/99 patients needed one or two additional pulses. Temporary leukopenia developed in 18/99 patients and diminished with the suspension or prolongation of the IV cyclophosphamide administration. Gastrointestinal side effects, which needed extra medication, developed in 20 patients. Hematuria was observed in 6/99 patients. Menstrual abnormalities were seen in 7/99 patients. No serious infections due to immunosuppression were observed with the given regimen. Hypertension was observed in 13 patients (minimum of 140/90 mmHg, maximum of 190/110 mmHg) and controlled with angiotensine-converting enzyme inhibitors. Mild central obesity was observed in 15 of the patients. Leimyosarcoma was observed in one patient who died during the follow-up period. Therapy starting with the weekly low-dose IV cyclophosphamide to induce remission together with IV and oral steroids, followed by prolonged intervals with the same doses for 2 years, appears to be useful in preserving renal function without major side effects in patients with lupus nephritis, in comparison to other studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Donadio JV, Hart GM, Bergstralh EJ, Holley KE (1995) Prognostic determinants in lupus nephritis: a long term clinicopathological study. Lupus 4:109–115

    PubMed  Google Scholar 

  2. Ward MM, Pyun E, Studenski S (1996) Mortality risk associated with specific clinical manifestations of systemic lupus erythematosus. Arch Intern Med 156:1337–1344

    Article  PubMed  CAS  Google Scholar 

  3. Vu TV, Escalante A (1999) A comparison of the quality of life of patients with systemic lupus erythematosus with and without end-stage renal disease. J Rheumatol 26:2595–2601

    PubMed  CAS  Google Scholar 

  4. Mok CC, Wong RWS, Lau CS (1999) Lupus nephritis in southern Chinese patients: clinicopathological findings and long-term outcome. Am J Kidney Dis 34:315–323

    PubMed  CAS  Google Scholar 

  5. Appel GB, Valeri A (1994) The course and treatment of lupus nephritis. Annu Rev Med 45:525–537

    Article  PubMed  CAS  Google Scholar 

  6. Bakir AA, Levy PS, Dunea G (1994) The prognosis of lupus nephritis in African-Americans: a retrospective analysis. Am J Kidney Dis 24:159–171

    PubMed  CAS  Google Scholar 

  7. Austin HA III, Klippel JH, Balow JE, le Riche NGH, Steinberg AD, Plotz PH, Decker JL (1986) Therapy of lupus nephritis: controlled trial of prednisone and cyctotoxic drugs. N Engl J Med 314:614–619

    Article  PubMed  Google Scholar 

  8. Steinberg AD, Steinberg SC (1991) Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those threaded with prednisone only. Arthritis Rheum 34:945–950

    PubMed  CAS  Google Scholar 

  9. Boumpas DT, Austin HA III, Voughan EM, Klippel JH, Steinberg AD, Yarboro CH et al (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741–751

    Article  PubMed  CAS  Google Scholar 

  10. Gourley MF, Austin HA III, Scott D, Yarboro CH, Voughan EM, Muir J et al (1996) Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. Ann Intern Med 125:549–557

    PubMed  CAS  Google Scholar 

  11. İllei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH et al (2001) Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 135:248–257

    Google Scholar 

  12. Pisoni CN, Karim Y, Cuadrado MJ (2005) Mycophenolate mofetil and systemic lupus erythematosus: an overview. Lupus 14(Suppl 1):9–11

    Article  Google Scholar 

  13. Thatayatikom A, White AJ (2006) Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev 5:18–24

    Article  PubMed  CAS  Google Scholar 

  14. Boumpas DT, Austin HA III, Vaughan EM, Yarboro CH, Klippel JH, Balow JE (1993) Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119:366–369

    PubMed  CAS  Google Scholar 

  15. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1991) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 34:945–950

    Google Scholar 

  16. Gordon C (2003) Assessing disease activity and out come in systemic lupus erythematosus. In: Hochberg MC, Silman A, Smolen JS, Weinblatt ME, Weisman MH (eds) Rheumatology. Mosby, Edinburgh, pp 1389–1393

    Google Scholar 

  17. Boumpas DT, Balow JE (1998) Outcome criteria for lupus nephritis trials: a critical overview. Lupus 7:622–629

    Article  PubMed  CAS  Google Scholar 

  18. Austin HA, Balow JE (1999) Natural history and treatment of lupus nephritis. Semin Nephrol 19:2–11

    PubMed  CAS  Google Scholar 

  19. Ortmann RA, Klippel JH (2000) Update on cyclophosphamide for systemic lupus erythematosus. Rheum Dis Clin North Am 26:363–375

    Article  PubMed  CAS  Google Scholar 

  20. D’Cruz D, Cuadrado MJ, Mujic F et al (1997) Immunosuppressive therapy in lupus nephritis. Clin Exp Rheumatol 15:275–282

    PubMed  CAS  Google Scholar 

  21. Houssiau FA, Vasconcelos C, D’cruz D, Sebastiani GD, Garrido ER, Danieli MG, Abramovicz D et al (2002) Immunosuppressive therapy in lupus nephritis. The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46:2121–2131

    Article  PubMed  CAS  Google Scholar 

  22. Martin-Suarez I, D’Cruz D, Mansoor M et al (1997) Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 56:481–487

    PubMed  CAS  Google Scholar 

  23. Mok CC, Kwan Ho CT, Siu YP, Chan KW, Kwan TH et al (2001) Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis 38:256–264

    PubMed  CAS  Google Scholar 

  24. Chan TM, Li FK, Wong RW et al (1995) Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Nephron 71:321–327

    Article  PubMed  CAS  Google Scholar 

  25. Golbus J, Mc Cune WJ (1994) Lupus nephritis. Classification, prognosis, immunopathogenesis and treatment. Rheum Dis Clin North Am 20:213–242

    PubMed  CAS  Google Scholar 

  26. Gladman DD, Krowitz MD (2000) Clinical features of SLE. Klippel Dieppe Sec. Edd. Mosby, London, pp 7.1.5–7.1.8

    Google Scholar 

  27. Contreras G, Pardo V, Leclercq B, Lenzo O, Tozman E, O’Nas P, Roth D (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350:971–980

    Article  PubMed  CAS  Google Scholar 

  28. Klinlen LJ (1985) Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 78(Suppl 1A):44–49

    Article  Google Scholar 

  29. Fox DA, McCune J (1994) Immunosuppressive therapy of systemic lupus erythematosus. Rheum Dis Clin North Am 20:265–299

    PubMed  CAS  Google Scholar 

  30. Abu-Shakra M, Gladman DD, Urowitz MB (1996) Malignancy in systemic lupus erythematosus. Arthritis Rheum 39:1050–1054

    PubMed  CAS  Google Scholar 

  31. Belmont HM, Storch M, Buyon J, Abramson S (1995) New York University/Hospital for joint disease experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis. Lupus 4:104–108

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Section of Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey

    Meral Calguneri, Zeynep Ozbalkan, Sule Apras, A. Ihsan Ertenli & Sedat Kiraz

  2. Department of Internal Medicine, Section of Rheumatology, Gazi University School of Medicine, Ankara, Turkey

    M. Akif Ozturk

  3. Sehit Ismail Eres Sok. Sahinler Apt 4/9, 06570, Maltepe, Ankara, Turkey

    Zeynep Ozbalkan

Authors
  1. Meral Calguneri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zeynep Ozbalkan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Akif Ozturk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sule Apras
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Ihsan Ertenli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sedat Kiraz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zeynep Ozbalkan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Calguneri, M., Ozbalkan, Z., Ozturk, M.A. et al. Intensified, intermittent, low-dose intravenous cyclophosphamide together with oral alternate-day steroid therapy in lupus nephritis (long-term outcome). Clin Rheumatol 25, 782–788 (2006). https://doi.org/10.1007/s10067-006-0217-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-006-0217-2

Keywords

Search

Navigation